1. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. (August 2015) Authors: Stewart, A Keith Journal: Future oncology Issue: Volume 11:Number 15(2015) Page Start: 2121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Carfilzomib: a novel second-generation proteasome inhibitor. (May 2011) Authors: Khan, Meaghan L; Stewart, A Keith Journal: Future oncology Issue: Volume 7:Number 5(2011) Page Start: 607 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Issue 10297 (24th July 2021) Authors: Berdeja, Jesus G; Madduri, Deepu; Usmani, Saad Z; Jakubowiak, Andrzej; Agha, Mounzer; Cohen, Adam D; Stewart, A Keith; Hari, Parameswaran; Htut, Myo; Lesokhin, Alexander; Deol, Abhinav; Munshi, Nikhil C; O'Donnell, Elizabeth; Avigan, David; Singh, Indrajeet; Zudaire, Enrique; Yeh, Tzu-Min; Allred... Journal: Lancet Issue: Volume 398:Issue 10297(2021) Page Start: 314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Issue 12 (December 2022) Authors: Martin, Thomas; Lin, Yi; Agha, Mounzer; Cohen, Adam D; Htut, Myo; Stewart, A Keith; Hari, Parameswaran; Berdeja, Jesus G; Usmani, Saad Z; Yeh, Tzu-Min; Olyslager, Yunsi; Goldberg, Jenna D; Schecter, Jordan M; Madduri, Deepu; Jackson, Carolyn C; Deraedt, William; Gries, Katharine S; Fastenau, John... Journal: Lancet Issue: Volume 9:Issue 12(2022) Page Start: e897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Issue 7 (July 2018) Authors: Moreau, Philippe; Mateos, Maria-Victoria; Berenson, James R; Weisel, Katja; Lazzaro, Antonio; Song, Kevin; Dimopoulos, Meletios A; Huang, Mei; Zahlten-Kumeli, Anita; Stewart, A Keith Journal: Lancet oncology Issue: Volume 19:Issue 7(2018) Page Start: 953 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Review of molecular diagnostics in multiple myeloma. (July 2007) Authors: Stewart, A Keith; Fonseca, Rafael Journal: Expert review of molecular diagnostics Issue: Volume 7:Number 4(2007) Page Start: 453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease. (10th October 2014) Authors: Kortüm, Klaus M.; Langer, Christian; Monge, Jorge; Bruins, Laura; Egan, Jan B.; Zhu, Yuan X.; Shi, Chang Xin; Jedlowski, Patrick; Schmidt, Jessica; Ojha, Juhi; Bullinger, Lars; Liebisch, Peter; Kull, Miriam; Champion, Mia D.; Van Wier, Scott; Ahmann, Gregory; Rasche, Leo; Knop, Stefan; Fonseca, R... Journal: British journal of haematology Issue: Volume 168:Number 4(2015:Feb.) Page Start: 507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗